Literature DB >> 27133489

Patient-Reported Outcomes in Psoriatic Arthritis.

Ana-Maria Orbai1, Alexis Ogdie2.   

Abstract

Patient-reported outcome (PRO) measures are an important component to assessing disease impact and therapy response in patients with psoriatic arthritis (PsA). Overall, there are few PsA-specific PROs. Most PROs used in PsA are borrowed from other diseases (eg, rheumatoid arthritis and ankylosing spondylitis) or general population PROs. PROs are used in PsA clinical trials and in the clinical management of PsA. In this review, we discuss the most commonly used PRO in PsA, including their inclusion in composite measures. Future studies may be helpful to determine the best performing PROs in patients with PsA.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Composite measures; Outcome measure; Patient reported outcome; Psoriatic arthritis

Mesh：

Year:  2016        PMID： 27133489      PMCID： PMC4853652          DOI： 10.1016/j.rdc.2016.01.002

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  95 in total

1.  RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.

Authors:  Theodore Pincus; Victoria Furer; Edward Keystone; Yusuf Yazici; Martin J Bergman; Kristel Luijtens
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-08       Impact factor: 4.794

2.  Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

Authors:  A Y Finlay; G K Khan
Journal:  Clin Exp Dermatol       Date:  1994-05       Impact factor: 3.470

3.  Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.

Authors:  David Cella; Susan Yount; Mark Sorensen; Elliot Chartash; Nishan Sengupta; James Grober
Journal:  J Rheumatol       Date:  2005-05       Impact factor: 4.666

4.  Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients.

Authors:  Lihi Eder; Arane Thavaneswaran; Vinod Chandran; Richard Cook; Dafna D Gladman
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-02       Impact factor: 4.794

5.  Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales.

Authors:  Tiffany Kwok; Janet E Pope
Journal:  J Rheumatol       Date:  2010-03-15       Impact factor: 4.666

6.  Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study.

Authors:  Alberto Cauli; Dafna D Gladman; Alessandro Mathieu; Ignazio Olivieri; Giovanni Porru; Paul P Tak; Claudia Sardu; Ilona Ujfalussy; Raffaele Scarpa; Antonio Marchesoni; William J Taylor; Antonio Spadaro; Jose L Fernàndez-Sueiro; Carlo Salvarani; Joachim R Kalden; Ennio Lubrano; Sueli Carneiro; Francesca Desiati; John A Flynn; Salvatore D'Angelo; Alessandra Vacca; Arno W R VAN Kuijk; Maria Grazia Catanoso; Mathias Gruenke; Rosario Peluso; Wendy J Parsons; Nicola Ferrara; Paolo Contu; Philip S Helliwell; Philip J Mease
Journal:  J Rheumatol       Date:  2011-02-15       Impact factor: 4.666

Review 7.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

8.  Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden.

Authors:  E Billing; S P McKenna; M Staun; U Lindqvist
Journal:  Scand J Rheumatol       Date:  2010-05       Impact factor: 3.641

Review 9.  Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11.

Authors:  Laura C Coates; Oliver FitzGerald; Philip J Mease; Dafna D Gladman; Vibeke Strand; Niti Goel; Ina Campbell; Gerald Krueger; Neil J McHugh; Philip S Helliwell
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

10.  Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA).

Authors:  Jane T Osterhaus; Oana Purcaru; Lance Richard
Journal:  Arthritis Res Ther       Date:  2009-05-20       Impact factor: 5.156
View more
  17 in total

1.  Posttraumatic stress disorder and correlates of disease activity among veterans with ankylosing spondylitis.

Authors:  Jean Liew; J Lucas Williams; Steven Dobscha; Jennifer L Barton
Journal:  Rheumatol Int       Date:  2017-08-24       Impact factor: 2.631

Review 2.  PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Authors:  Ana-Maria Orbai; Richard Holland; Ying Ying Leung; William Tillett; Niti Goel; Robin Christensen; Neil McHugh; Laure Gossec; Maarten de Wit; Pil Højgaard; Laura C Coates; Philip J Mease; Julie Birt; Lara Fallon; Oliver FitzGerald; Alexis Ogdie; Beverly Shea; Vibeke Strand; Kristina Callis Duffin; Peter Tugwell; Dorcas Beaton; Dafna D Gladman
Journal:  J Rheumatol       Date:  2018-12-15       Impact factor: 4.666

Review 3.  The Changing Face of Clinical Trials in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura Coates
Journal:  Curr Rheumatol Rep       Date:  2017-04       Impact factor: 4.592

Review 4.  Tumor necrosis factor inhibitors in psoriatic arthritis.

Authors:  Santhi Mantravadi; Alexis Ogdie; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2017-05-22       Impact factor: 5.045

Review 5.  Selecting patient-reported outcome measures of health-related quality of life in adult rheumatology: quality and breadth of coverage.

Authors:  Erin Knight; Karen E Schifferdecker; Guy S Eakin; Bryce B Reeve
Journal:  Rheumatol Int       Date:  2022-09-20       Impact factor: 3.580

6.  Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

Authors:  Vibeke Strand; Kurt de Vlam; Jose A Covarrubias-Cobos; Philip J Mease; Dafna D Gladman; Linda Chen; Elizabeth Kudlacz; Joseph Wu; Joseph C Cappelleri; Thijs Hendrikx; Ming-Ann Hsu
Journal:  RMD Open       Date:  2019-01-11

7.  Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Authors:  Ana-Maria Orbai; Maarten de Wit; Philip J Mease; Kristina Callis Duffin; Musaab Elmamoun; William Tillett; Willemina Campbell; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Laure Gossec; Pil Hoejgaard; Ying Ying Leung; Chris Lindsay; Vibeke Strand; Désirée M van der Heijde; Bev Shea; Robin Christensen; Laura Coates; Lihi Eder; Neil McHugh; Umut Kalyoncu; Ingrid Steinkoenig; Alexis Ogdie
Journal:  J Rheumatol       Date:  2017-02-01       Impact factor: 4.666

8.  Prevalence and Characterization of Fatigue in Patients with Skin Diseases.

Authors:  Laurent Misery; Jason Shourick; Charles Taïeb
Journal:  Acta Derm Venereol       Date:  2020-11-18       Impact factor: 3.875

9.  Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).

Authors:  Ana-Maria Orbai; Alexis Ogdie; Laure Gossec; William Tillett; Ying Ying Leung; Jingjing Gao; Mona Trivedi; Chantal Tasset; Luc Meuleners; Robin Besuyen; Thijs Hendrikx; Laura C Coates
Journal:  Rheumatology (Oxford)       Date:  2020-07-01       Impact factor: 7.580

10.  Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study.

Authors:  Ana F Souza; Michael R Da Silva; Jéssica B Dos Santos; Alessandra M Almeida; Francisco A Acurcio; Juliana Alvares-Teodoro
Journal:  Pharm Pract (Granada)       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.